Table 4.
Correlation between Srx, PROX1 and Nrf2 levels in the studied patients and treatment-specific characteristics and patients’ outcome
| Parameter | Srx level | p-value# | PROX1 | p-value | Nrf2 | p-value# | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Low n = 21 (42%) |
High n = 29 (58%) |
Low n = 28 (56%) |
High n = 22 (44%) |
Low n = 21 (42%) |
High n = 29 (58%) |
|||||
| Response | 0.002* | 0.003* | 0.017* | |||||||
| PD | 0 (0) | 9 (31) | 9 (32.1) | 0 (0) | 1 (4.8) | 8 (27.6) | ||||
| SD | 0 (0) | 4 (13.5) | 4 (14.3) | 0 (0) | 0 (0) | 4 (13.8) | ||||
| PR | 1 (4.8) | 3 (10.3) | 2 (7.1) | 2 (9.1) | 1 (4.8) | 3 (10.3) | ||||
| CR | 20 (95.2) | 13 (44.8) | 13 (46.4) | 20 (90.9) | 19 (90.5) | 14 (48.3) | ||||
| Relapse (33) | 0.004* | 0.004* | 0.09 | |||||||
| Free | 12 (60) | 1 (8) | 1 (8) | 12 (60) | 10 (52.6) | 3 (21.4) | ||||
| Present | 8 (40) | 12 (92) | 12 (92) | 8 (40) | 9 (47.4) | 11 (78.6) | ||||
| Outcome | < 0.001** | < 0.001** | < 0.001** | |||||||
| Alive | 20 (95.2) | 2 (6.9) | 2 (7.1) | 20 (90.9) | 18 (85.7) | 4 (13.8) | ||||
| Dead | 1 (4.8) | 27 (93.1) | 26 (92.9) | 2 (9.1) | 3 (14.3) | 25 (86.2) | ||||
| Disease-free survival | < 0.003*¥ | 0.003*¥ | 0.005*¥ | |||||||
| Median | 40 | 30 | 30 | 40 | 40 | 30 | ||||
| Range | 13–58 | 15–40 | 15–40 | 13–58 | 13–58 | 15–40 | ||||
| Overall survival | < 0.001**∞ | < 0.001**∞ | < 0.001**∞ | |||||||
| Mean ±SD | 40.8 ±12.98 | 31.92 ±8.68 | 31.92 ±8.68 | 40.8 ±12.98 | 37.9 ±16 | 21.5 ±12.6 | ||||
| Range | 13–58 | 20–50 | 20–50 | 13–58 | 13–58 | 20–50 | ||||
¥
Z Mann-Whitney test, # χ2 test, ∞ independent sample test, * p < 0.05 is statistically significant, ** p ≤ 0.001 is statistically highly significant